Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6692377 | 0.81 | LMNA (0.58) | SMN1; SMN2KMT2ATP53ALDH1A1NPSR1 | |
| SCHEMBL6694189 | 0.80 | TUBB1 (0.54) | KMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL6692393 | 0.79 | THRB (0.39) | SMN1; SMN2GAAKMT2AALDH1A1MAPT | |
| SCHEMBL6693009 | 0.79 | KDM4E (0.49) | SMN1; SMN2KMT2AMAPK1ALDH1A1MAPT | |
| SCHEMBL17489182 | 0.78 | L3MBTL1 (0.41) | SMN1; SMN2GAAKMT2AMAPK1L3MBTL1 | |
| SCHEMBL31192656 | 0.77 | THRB (0.43) | SMN1; SMN2GAAKMT2ATP53L3MBTL1 | |
| SCHEMBL6693303 | 0.77 | TUBB1 (0.46) | SMN1; SMN2GAAL3MBTL1ALDH1A1MAPT | |
| SCHEMBL11660334 | 0.76 | POLB (0.34) | SMN1; SMN2GAAKMT2ATP53L3MBTL1 | |
| SCHEMBL13297307 | 0.75 | L3MBTL1 (0.57) | SMN1; SMN2GAAKMT2AMAPK1TP53 | |
| SCHEMBL30965843 | 0.74 | L3MBTL1 (0.64) | SMN1; SMN2GAAKMT2AMAPK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747048-B2 | TREATING DISEASES OR DISORDERS ASSOCIATED WITH METABOLISM DYSFUNCTION OR WHICH ARE DEPENDENT UPON THE EXPRESSION OF A T3 REGULATED GENE, | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-08 | — | — | US | disclosed |
| US-20040039028-A1 | Pyridine-based thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039028-A1 | Pyridine-based thyroid receptor ligands | TSHR, THRB, THRA | SMN1; SMN2 3943/4885GAA 4733/4885KMT2A 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.